Oxular was mentioned in this great article by Dr. Sivaprasad in Retina Today, on the promise of reduced treatment burden for DME patients via sustained-release steroids. Oxular is a key innovator in long-lasting retinal treatments and precise suprachoroidal space delivery, and some of the advantages behind our approach are highlighted here. Simply put, we believe it’s going to lead to better outcomes for patients, physicians and healthcare systems. Our lead program combines our Oxulumis®️ microcatheter and a sustained-release formulation of dexamethasone to target 12 months treatment durability for DME. We’re preparing clinical trials now.
Oxular Limited, Magdalen Centre, 1 Robert Robinson Avenue, Oxford OX4 4GA, UK
Limited company registered in England and Wales (Registration No. 09331313)
VAT No. GB 244 5883 81
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.